Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)
Completed
Pfizer
Phase 3
2010-12-01
This study will evaluate the impact of Xiapex treatment on the range of motion (ROM) of the
affected fingers and the patient and physician reported treatment satisfaction and disease
severity and their relation to ROM. Recovery to normal activities, recovery time (How long
overall, time to use hand, time to return to work or daily activities, amount of work or
daily activity time missed or reduced and affects on productivity and daily activities) will
be assessed via patient diary. Use of concomitant analgesic medications will be recorded and
total healthcare resource utilization (HCRU).
Collagenase Option for Reduction of Dupuytren's Contracture in Japan
Completed
Asahi Kasei Pharma Corporation
Phase 3
2012-05-01
To investigate the efficacy and safety of AK160 in patients with Dupuytren's Contracture.
To determine plasma concentration after the first injection of AK160 in patients with
Dupuytren's Contracture.
A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma
Completed
Advance Biofactures Corporation
Phase 2
2012-05-01
The purpose of this research is to evaluate the safest and most effective dose of a Food and
Drug Administration (FDA) approved drug (XIAFLEX) in the treatment of lipoma (fatty tumors of
varying sizes that occur commonly in the adult population). The fat in the lipoma is like
normal fat except that it is enclosed in a balloon-like structure which is made of collagen
(fibrous tissue). Treatment of the lipoma with an injection of XIAFLEX (a protein that breaks
down collagen fibers) may dissolve the collagen/fibrous strands thereby decreasing the size
of the lipoma or removing it.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.